Linkdoc technology8/14/2023 ![]() Even though the company has a data advantage, the fact is that finding the causes and treatments for oncological diseases is extremely complicated and subject to stringent regulatory requirements. LinkDoc is still in the early stages and there is considerable risk with the technology. What’s more, the market for oncology big data went from $500 million in 2015 to $2.1 billion in 2019 and is forecasted to reach $119.6 billion by 2030. Regarding oncology, it has the highest growth rate for the patient pool. ![]() Consider that China has the world’s second largest healthcare market and the spending is expected to increase at close to 10% per year until 2030, reaching $2.529 trillion. Yet the market opportunity is substantial. During the latest quarter, the revenues jumped by 41% to $34.1 million. This not only has provided for next-generation treatments but has allowed for a rich source of data collection.Īs for the growth rate, it has been robust. These systems also interact with each other, such as with data integration.Īnother key to the strategy is a nationwide network of 34 patient care centers. There is LinkCare for continuous care for disease, LinkData for AI-based curation based on longitudinal medical data and LinkSolutions for helping life science companies accelerate drug development. The company has three different offerings. According to research from Frost & Sullien, LinkDoc has the largest dataset of China’s oncology cohorts and has built the most extensive digital infrastructure for precision medicine. Perhaps the most important is its trove of valuable data. Nevertheless, LinkDoc has some major advantages. After all, companies like IBM ( IBM) have tried to do the same thing but have faced major challenges. The core vision of LinkDoc is to use precision medicine and personalized care to essentially uncover the story of every patient. So then, let’s take a deeper look at the company as well as what we may see about Chinese IPOs. ![]() The fact is that there are major regulatory shifts in China. Of course, this was not necessarily about the company. (See IPO Calendar on TipRanks) It looked like the deal had traction with investors, with the valuation at about $1.5 billion.īut unfortunately, LinkDoc suspended the offering. In May, Reuters reported that Beijing was pressing audio platform Ximalaya to drop US listing plans and opt for Hong Kong instead, with one source at the time citing Beijing's concerns that US regulators will potentially gain more access to audit documents of New York-listed Chinese companies.Īnalysts also note the tougher stance coincides with new US regulations being rolled out that could see Chinese companies delisted if they do not comply with US auditing rules.LinkDoc Technology, which is a China-based company that leverages sophisticated data technologies for oncology patients, was expected to pull off its IPO last week. The tougher stance by the Cybersecurity Administration of China has been driven in part by concerns that the United States could gain greater access to data owned by Chinese firms - similar to concerns that the previous Trump administration had voiced about Chinese firms operating in the United States. So far this year, a record $12.5 billion by Chinese firms has been raised from 34 US listings, Refinitiv data shows, well up from the $1.9 billion from 14 deals in the same period a year ago.Įight Chinese companies including home service platform Daojia Ltd and Atour Lifestyle Holdings have made public filings with the Securities and Exchange Commission (SEC) to list in the US later this year, a review of the filings showed. US capital markets have been a lucrative source of funding for Chinese firms in the past decade, especially for technology companies looking to benchmark their valuations against listed peers there and tap an abundant liquidity pool. Morgan Stanley and Bank of America declined to comment, while CICC did not respond to a Reuters request for comment. Morgan Stanley, Bank of America, and China International Capital Corp Ltd (CICC) were the investment banks on the deal. LinkDoc did not immediately respond to a request for comment. The sources declined to be identified as the information has not yet been made public. The book closed one day earlier than planned on Wednesday, one of the three sources and a separate person said. It had planned to sell 10.8 million shares between $17.50 and $19.50 each.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |